glp-1 obesity news Researchers find medications safe to continue before surgery in patients with diabetes and Obesity Clinical Trials | Expert

Description

Our findings strongly suggest the answer is yes. Primes recent real-world study found 63% of high-potency GLP-1 (Wegovy or Zepbound) users who started treatment in Q1 2024 are still taking their medication after a year

Expertly prescribed medications to enhance your weight loss journey.

THIRD-PARTY TESTED, AND DOCTOR RECOMMENDED: Manufactured in the USA in FDA-reviewed, NSF and GMP certified facilities to ensure the highest standards of safety and effectiveness

The result? Faster progress and a smoother, more comfortable path toward your health goals

The combination therapy of GLP-1 receptor agonists and metformin demonstrates superior safety over monotherapy, while revealing novel adverse events and demographic-specific risk patterns, thereby offering reliable evidence to inform clinical practice.